172 related articles for article (PubMed ID: 30658234)
21. Structural basis of the ligand binding and signaling mechanism of melatonin receptors.
Wang Q; Lu Q; Guo Q; Teng M; Gong Q; Li X; Du Y; Liu Z; Tao Y
Nat Commun; 2022 Jan; 13(1):454. PubMed ID: 35075127
[TBL] [Abstract][Full Text] [Related]
22. Melatonin MT
López-Canul M; Min SH; Posa L; De Gregorio D; Bedini A; Spadoni G; Gobbi G; Comai S
Int J Mol Sci; 2019 May; 20(10):. PubMed ID: 31108968
[TBL] [Abstract][Full Text] [Related]
23. Efficient synthesis of hexahydroindenopyridines and their potential as melatoninergic ligands.
Párraga J; Moreno L; Diaz A; El Aouad N; Galán A; Sanz MJ; Caignard DH; Figadère B; Cabedo N; Cortes D
Eur J Med Chem; 2014 Oct; 86():700-9. PubMed ID: 25232966
[TBL] [Abstract][Full Text] [Related]
24. Alternative Radioligands for Investigating the Molecular Pharmacology of Melatonin Receptors.
Legros C; Brasseur C; Delagrange P; Ducrot P; Nosjean O; Boutin JA
J Pharmacol Exp Ther; 2016 Mar; 356(3):681-92. PubMed ID: 26759496
[TBL] [Abstract][Full Text] [Related]
25. Synthesis and biological activity of new melatonin dimeric derivatives.
Di Giacomo B; Bedini A; Spadoni G; Tarzia G; Fraschini F; Pannacci M; Lucini V
Bioorg Med Chem; 2007 Jul; 15(13):4643-50. PubMed ID: 17481904
[TBL] [Abstract][Full Text] [Related]
26. Orphan GPR61, GPR62 and GPR135 receptors and the melatonin MT
Oishi A; Karamitri A; Gerbier R; Lahuna O; Ahmad R; Jockers R
Sci Rep; 2017 Aug; 7(1):8990. PubMed ID: 28827538
[TBL] [Abstract][Full Text] [Related]
27. Melatonin receptor heterodimerization in a photoreceptor-like cell line endogenously expressing melatonin receptors.
Sánchez-Bretaño A; Suen TC; Baba K; DeBruyne J; Tosini G
Mol Vis; 2019; 25():791-799. PubMed ID: 31819341
[TBL] [Abstract][Full Text] [Related]
28. Neurochemical properties of ramelteon (TAK-375), a selective MT1/MT2 receptor agonist.
Kato K; Hirai K; Nishiyama K; Uchikawa O; Fukatsu K; Ohkawa S; Kawamata Y; Hinuma S; Miyamoto M
Neuropharmacology; 2005 Feb; 48(2):301-10. PubMed ID: 15695169
[TBL] [Abstract][Full Text] [Related]
29. Synthesis and pharmacological evaluation of pentacyclic 6a,7-dihydrodiindole and 2,3-dihydrodiindole derivatives as novel melatoninergic ligands.
Attia MI; Witt-Enderby PA; Julius J
Bioorg Med Chem; 2008 Aug; 16(16):7654-61. PubMed ID: 18657980
[TBL] [Abstract][Full Text] [Related]
30. New MT₂ Melatonin Receptor-Selective Ligands: Agonists and Partial Agonists.
Boutin JA; Bonnaud A; Brasseur C; Bruno O; Lepretre N; Oosting P; Coumailleau S; Delagrange P; Nosjean O; Legros C
Int J Mol Sci; 2017 Jun; 18(7):. PubMed ID: 28644418
[TBL] [Abstract][Full Text] [Related]
31. C-terminal domains within human MT1 and MT2 melatonin receptors are involved in internalization processes.
Sethi S; Adams W; Pollock J; Witt-Enderby PA
J Pineal Res; 2008 Sep; 45(2):212-8. PubMed ID: 18341518
[TBL] [Abstract][Full Text] [Related]
32. Melatonin receptor signaling in pregnant and nonpregnant rat uterine myocytes as probed by large conductance Ca2+-activated K+ channel activity.
Steffens F; Zhou XB; Sausbier U; Sailer C; Motejlek K; Ruth P; Olcese J; Korth M; Wieland T
Mol Endocrinol; 2003 Oct; 17(10):2103-15. PubMed ID: 12869590
[TBL] [Abstract][Full Text] [Related]
33. MT1 and MT2 Melatonin Receptors: A Therapeutic Perspective.
Liu J; Clough SJ; Hutchinson AJ; Adamah-Biassi EB; Popovska-Gorevski M; Dubocovich ML
Annu Rev Pharmacol Toxicol; 2016; 56():361-83. PubMed ID: 26514204
[TBL] [Abstract][Full Text] [Related]
34. Preparation of 4-azaindole and 7-azaindole dimers with a bisalkoxyalkyl spacer in order to preferentially target melatonin MT1 receptors over melatonin MT2 receptors.
Larraya C; Guillard J; Renard P; Audinot V; Boutin JA; Delagrange P; Bennejean C; Viaud-Massuard MC
Eur J Med Chem; 2004 Jun; 39(6):515-26. PubMed ID: 15183910
[TBL] [Abstract][Full Text] [Related]
35. Real-Time Determination of Intracellular cAMP Reveals Functional Coupling of G
Tse LH; Cheung ST; Lee S; Wong YH
Int J Mol Sci; 2024 Mar; 25(5):. PubMed ID: 38474167
[TBL] [Abstract][Full Text] [Related]
36. New quinoxaline derivatives as potential MT₁ and MT₂ receptor ligands.
Ancizu S; Castrillo N; Pérez-Silanes S; Aldana I; Monge A; Delagrange P; Caignard DH; Galiano S
Molecules; 2012 Jun; 17(7):7737-57. PubMed ID: 22732886
[TBL] [Abstract][Full Text] [Related]
37. Docking studies for melatonin receptors.
Alkozi HA; Sánchez Montero JM; Doadrio AL; Pintor J
Expert Opin Drug Discov; 2018 Mar; 13(3):241-248. PubMed ID: 29271261
[TBL] [Abstract][Full Text] [Related]
38. Heterocyclic aminopyrrolidine derivatives as melatoninergic agents.
Sun LQ; Chen J; Mattson RJ; Epperson JR; Deskus JA; Li WS; Takaki K; Hodges DB; Iben L; Mahle CD; Ortiz A; Molstad D; Ryan E; Yeleswaram K; Xu C; Luo G
Bioorg Med Chem Lett; 2003 Dec; 13(24):4381-4. PubMed ID: 14643330
[TBL] [Abstract][Full Text] [Related]
39. Synthesis and biological evaluation of new naphtho- and quinolinocyclopentane derivatives as potent melatoninergic (MT
Duroux R; Rami M; Landagaray E; Ettaoussi M; Caignard DH; Delagrange P; Melnyk P; Yous S
Eur J Med Chem; 2017 Dec; 141():552-566. PubMed ID: 29102176
[TBL] [Abstract][Full Text] [Related]
40. New radioligands for describing the molecular pharmacology of MT1 and MT2 melatonin receptors.
Legros C; Matthey U; Grelak T; Pedragona-Moreau S; Hassler W; Yous S; Thomas E; Suzenet F; Folleas B; Lefoulon F; Berthelot P; Caignard DH; Guillaumet G; Delagrange P; Brayer JL; Nosjean O; Boutin JA
Int J Mol Sci; 2013 Apr; 14(5):8948-62. PubMed ID: 23698757
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
